Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 5, 2007, Pages 897-904

  de Latour, Régis Peffault ^a   Chaoui, Driss ^a   Bourhis, Jean Henri ^b   Belhocine, Ramdane ^c   Park, Sophie ^d   Legrand, Ollivier ^c   Brault, Philippe ^a   Rio, Bernard ^c   Heshmati, F ^d   Assouad, Sabine ^a   Decaudin, Didier ^a  

^a INSTITUT CURIE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Hôet Dieu ^*  (France)

^d Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; CYTARABINE; DEXAMETHASONE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CD34 SELECTION; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTAPHERESIS; DRUG FEVER; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; THROAT DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELLS;

EID: 34547407140     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701281497     Document Type: Article

References (48)

1. Gratwohl, A., Baldomero, H., Passweg, J. and Urbano-Ispizua, A. (2002) Increasing use of reduced intensity conditioning transplants: Report of the 2001 EBMT activity survey. Bone Marrow Transplant, 30, pp. 813-831.
2. Schmitz, N., Linch, D. C., Dreger, P., Goldstone, A. H., Boogaerts, M. A. and Ferrant, A. (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet, 347, pp. 353-357.
3. Nademanee, A., Sniecinski, I., Schmidt, G. M., Dagis, A. C., O'Donnell, M. R. and Snyder, D. S. (1994) High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol, 12, pp. 2176-2186.
4. Kamel, A. M., El-Sharkawy, N., Mahmoud, H. K., Khalaf, M. R., Haddad, A El and Fahmy, O. (2005) Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant, 35, pp. 129-136.
5. Shepherd, K. M., Charles, P., Sage, R. E., Dale, B. M., Norman, J. E. and Kotasek, D. (1991) Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol, 13, pp. 25-32.
6. Tarella, C., Ferrero, D., Bregni, M., Siena, S., Gallo, E. and Pileri, A. (1991) Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J cancer, 27, pp. 22-27.
7. Craig, J. I., Anthony, R. S., Stewart, A., Thomson, E. B., Gillon, J. and Parker, A. C. (1993) Peripheral blood stem cell mobilization using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma. Br J Haematol, 85, pp. 210-212.
8. Pavone, V., Gaudio, F., Guarini, A., Perrone, T., Zonno, A. and Curci, P. (2002) Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant, 29, pp. 285-290.
9. Lerro, K. A., Medoff, E., Seropian, S. E., Snyder, E. and Krause, D. (2003) A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant, 32, pp. 113-117.
10. Olivieri, A., Offidani, M., Ciniero, L., Cantori, I., Ombrosi, L. and Mancini, S. (1995) DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant, 16, pp. 85-93.
11. Emmanouilides, C., Territo, M., Andrey, J. and Mason, J. (2001) A randomized phase II study of amifostine used as stem cell protectant in non-hodgkin lymphoma patients receiving cisplatin-based salvage chemotherapy prior to stem cell transplant. J Hematother Stem Cell Res, 10, pp. 887-893.
12. Clark, A. D., Douglas, K. W., Mitchell, L. D., McQuaker, I. G., Parker, A. N. and Tansey, P. J. (2002) Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment. Br H Haematol, 117, pp. 605-612.
13. Smardova, L., Engert, A., Haverkamp, H., Raemakers, J., Baars, J. and Pfistner, B. (2005) Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma, 46, pp. 1017-1022.
14. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H. and Bron, D. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333, pp. 1540-1545.
15. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. and Bouabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
16. Habermann, T. M., Weller, E., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A. and Cohn, J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol, 24, pp. 3121-3127.
17. Pfreundschuh, M., Truemper, L., Osterborg, A., Pettengell, R., Trneny, M. and Imrie, K. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet, 7, pp. 379-391.
18. Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J. and Grillo-Lopez, A. J. (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol, 22, pp. 4711-4716.
19. Salles, G., Foussard, C., Mounier, N., Morschhauser, F., Doyen, C. and Lamy, T. (2004) Rituximab added to αIFN +CHVP improves the outcome of folicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood, 104
20. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E. and Schmits, R. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, pp. 3725-3732.
21. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E. and Catalano, J. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, pp. 1417-1423.
22. Lefrere, F., Delmer, A., Suzan, F., Levy, V., Belanger, C. and Djabarri, M. (2002) Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: A prospective study. Leukemia, 16, pp. 587-593.
23. Joyce, R. M., Kraser, C. N., Tetrealt, J. C., Giallombardo, N., McDermott, D. and Levine, J. (2001) Rituximab and ifosfamide, mitoxantrone, etoposide (RIME;with neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Eur J Haematol, 66, pp. 56-62.
24. Emmanouilides, C., Lill, M., Telatar, M., Rosenfelt, F., Grody, W. and Territo, M. (2002) Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma. Clin Lymphoma, 3, pp. 111-116.
25. Bieker, R., Kessler, T., Berdel, W. E. and Mesters, R. M. (2003) Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. Oncol Rep, 10, pp. 1915-1917.
26. Harris, N. L., Jaffe, E. S., Diébold, J., Flandrin, G., Muller-Hermelink, H. K. and Vardiman, J. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
27. Oken, M. M., Creech, R. H., Tormay, D. C., Horton, J., Davis, T. E. and McFadden, E. T. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, pp. 649-655.
28. (1993) A predictive model for aggressive non-Hodgkin's lymphoma: The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med, 329, pp. 987-994.
29. Cheson, B. D., Horning, J. S., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, pp. 1244-1253.
30. Cox, D. R. (1972) Regression models and life tables. J Roy Stat Soc, 34, pp. 187-220.
31. Magni, M., Nicola, M Di, Devizzi, L., Matteucci, P., Lombardi, F. and Gandola, L. (2000) Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood, 96, pp. 864-869.
32. Benekli, M., Hahn, T., Shafi, F., Qureshi, A., Alam, A. R. and Czuczman, M. S. (2003) Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant, 32, pp. 139-143.
33. Endo, T., Sato, N., Mogi, Y., Koizumi, K., Nishio, M. and Fujimoto, K. (2004) Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant, 33, pp. 703-707.
34. Hoerr, A. L., Gao, F., Hidalgo, J., Tiwari, D., Blum, K. A. and Mathews, V. (2004) Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non Hodgkin's lymphoma. J Clin Oncol, 22, pp. 4561-4566.
35. Bensinger, W., Appelbaum, F., Rowley, S., Storb, R., Sanders, J. and Lilleby, K. (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol, 13, pp. 2547-2555.
36. Goldschmidt, H., Hegenbart, U., Wallmeier, M., Hohaus, S. and Haas, R. (1997) Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol, 98, pp. 736-744.
37. Ketterer, N., Salles, G., Moullet, I., Dumontet, C., ElJaafari-Corbin, A. and Tremisi, P. (1998) Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol, 103, pp. 235-422.
38. Kobbe, G., Sohngen, D., Bauser, U., Schneider, P., Germing, U. and Thiele, K. P. (1999) Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. Ann Hematol, 78, pp. 456-462.
39. Haas, R., Moos, M., Karcher, A., Mohle, R., Witt, B. and Goldschmidt, H. (1994) Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol, 12, pp. 1685-1692.
40. Perea, G., Sureda, A., Martino, R., Altes, A., Martinez, C. and Cabezudo, E. (2001) Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol, 80, pp. 592-597.
41. Gordan, L. N., Sugrue, M. W., Lynch, J. W., Williams, K. D., Khan, S. A. and Wingard, J. R. (2003) Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma, 44, pp. 815-820.
42. Jantunen, E., Kuittinen, T. and Nousiainen, T. (2003) Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lymphoma?. Bone Marrow Transplant, 32, pp. 569-573.
43. Buckstein, R., Imrie, K., Spaner, D., Potichnyj, A., Robinson, J. B. and Nanji, S. (1999) Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol, 5, pp. 115-122.
44. Flinn, I. W., O'Donnell, P. V., Goodrich, A., Vogelsang, G., Abrams, R. and Noga, S. (2000) Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant, 6, pp. 628-632.
45. Voso, M. T., Pantel, G., Weis, M., Schmidt, P., Martin, S. and Moos, M. (2000) In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol, 109, pp. 729-735.
46. Gisselbrecht, C. and Mounier, N. (2003) Rituximab: Enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. Semin Oncol, 30, pp. 28-33.
47. Hertzberg, M. S., Crombie, C., Benson, W., Taper, J., Gottlieb, D. and Bradstock, K. F. (2003) Outpatient-based ifosfamide, carboplatin and etoposide (ICE;chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol, 14, p. i11.
48. Kewalramani, T., Zelenetz, A. D., Nimer, S. D., Portlock, C., Straus, D. and Noy, A. (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103, pp. 3684-3688.